en · de · es · fr · pt
cjc-1295-notes.peptides4962.com › Data › Background And Molecular Design — Worked Examples

Background And Molecular Design — Worked Examples

By Editorial Desk · published 2025-10-29 · last reviewed 2025-11-30 · Data

Albumin binding comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2025-11-30. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Molecular Design

CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.

Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.

Receptor Action and Clearance

Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.

Cjc-1295 at a glance

PropertyValueNotes
Primary targetGHRH receptorPresent on pituitary somatotroph cells
Signal pathwayGs, cyclic AMP, protein kinase ASequence follows receptor activation
Main measured effectGrowth hormone releaseInsulin-like growth factor 1 shifts indirectly
Half-life, binding formSeveral daysExtended through serum albumin association
Half-life, unmodified formAbout 30 minutesLimited mainly by enzymatic cleavage

Albumin Binding and Duration of Action

Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.

The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.

Related pages on this site

Background and Receptor Mechanism

At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.

CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.

Handling, Stability and Analysis

Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.

Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.

Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.

Supporting material

The hot filament reaches a temperature of less than 2,500 °C (2,770 K; 4,530 °F), leading to the inability to create atomic ions of species with a high ionization energy, such as osmium and tungsten. Although the TIMS method can create molecular ions instead in this case, species with high ionization energy can be analyzed more effectively with MC-ICP-MS.

Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the pyridopyrroloquinoxaline and butyrophenone families. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy (with lithium or valproate), and for major depressive disorder as an adjunctive therapy only (with an oral antidepressant). It is developed by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb. Lumateperone was approved for medical use in the US in December 2019 with an initial indication for schizophrenia. It became available in February 2020.

== Overdose == Enobosarm has been assessed in clinical trials at doses ranging from 0.1 to 18 mg/day. However, most research has been done at doses of 0.1 to 3 mg/day, with two phase 3 clinical trials using a dosage of 3 mg/day. A few small phase 1 and phase 2 trials of enobosarm for breast cancer have employed doses of 9 to 18 mg/day. Larger, phase 3 trials of enobosarm at a dose of 9 mg/day for breast cancer (e.g., ARTEST, n=210) are now underway. Doses of up to 100 mg have been assessed in single-dose pharmacokinetic studies and doses of up to 30 mg/day have been given in short 14-day pharmacokinetic studies. Enobosarm sold via black-market Internet suppliers and used non-medically is often taken at much higher doses than those used widely in clinical trials (e.g., 10–30 mg/day), with unknown adverse effects and risks.

==== Menstrual bleeding ==== Menstrual bleeding is a common cause of iron deficiency anemia in women of childbearing age. Women with menorrhagia (heavy menstrual periods) are at risk of iron deficiency anemia because they are at a higher than normal risk of losing more iron during menstruation than is replaced in their diet. Most women lose about 40 mL of blood per cycle. Some birth control methods, such as pills and IUDs, may decrease the amount of blood and therefore iron lost during a menstrual cycle. Intermittent iron supplementation may be as effective a treatment in these cases as daily supplements and reduce some of the adverse effects of long-term daily supplements.

Sources: en.wikipedia.org

Supporting material

=== Aging === Tissue homeostasis generally declines with age, in part because stem/progenitor cells fail to self-renew or differentiate. Skin aging is caused in part by TGF-β by blocking the conversion of dermal fibroblasts into fat cells which provide support. Common changes in the skin as a result of aging range from wrinkles, discoloration, and skin laxity, but can manifest in more severe forms such as skin malignancies. Moreover, these factors may be worsened by sun exposure in a process known as photoaging.

== Clinical Significance == In diseases related to the cartilage, the territorial matrix undergoes structural and material changes, leading to degradation of the joints, like in the case of osteoarthritis. Osteoarthritis occurs when the proteoglycans and collagen fibers degrade and become disorganized. Consequently, the decreased mechanical support makes chondrocytes more vulnerable to damage. Matrix-degrading enzymes including matrix metalloproteinases (MMPs) target the region which can accelerate cartilage degradation. Attempts to restore a functional territorial matrix is a particular area of interest in tissue engineering and cartilage repair, since its structure significantly contributes to optimal mechanical and biochemical behavior. Studies on biomimetic proteoglycans, which mimic the natural existing component of the ECM, and their effect on neighboring cartilage regions have shown promising results for strengthening cartilage with osteoarthritis. Additionally, biomaterials designed to mimic native composition and mechanical properties of cartilage, especially those with synthetic proteoglycans or collagen, have shown experimental promise. In combination with these structures, the durability of engineering cartilage may be enhanced by regenerating the territorial matrix and could improve integration with native tissue.

If you can watch that back and call that serious, then (looking at the promoter) you're f...d, and KSW is going down the f...g toilet." Two days later the promotion changed the result to a No Contest. During a conference held on 28 November, the ruling was deemed to be a "judge's error" and the fight result was changed. Mariusz's next opponent was Bob Sapp in a fight took place in Łódź, Poland on KSW 19 on 12 May 2012. Mariusz won via a TKO in the first round, battering Sapp with a barrage of punching and securing a takedown followed with more punches to win just 39 seconds into the fight. Mariusz then faced Christos Piliafas on 15 September in the main event of KSW 20. Mariusz won via TKO in the first round, after dominating Piliafas on his feet, he then secured a takedown followed by posturing up and raining down some ground and pound to win at 3:48 seconds into the fight. On 8 June 2013, Pudzianowski fought Sean McCorkle at KSW 23, losing the bout in the first round by kimura submission. Pudzianowski fought McCorkle again in a rematch on 28 September at KSW 24, avenging his loss via unanimous decision. After the second fight, Sean McCorkle expressed interest in a third fight. On 17 May 2014 at KSW 27, Pudzianowski defeated Oli Thompson via a 2nd round unanimous decision. During the fight, Pudzianowski was able to gain points by controlling the entire fight through landing punches and securing multiple takedowns in both rounds eventually leading to his victory. At the end, Thompson requested a rematch, to which Pudzianowski agreed.

The brisket muscles are sometimes separated for retail cutting: the lean "first cut" or "flat cut" is the deep pectoral, while the fattier "second cut", "point", "fat end", or "triangular cut" is the superficial pectoral. For food service use, they are IMPS 120A and 120B, respectively.

Those who cannot tolerate ACE inhibitors may be treated with an angiotensin II receptor antagonist. Statin therapy has been shown to reduce mortality and subsequent cardiac events and should be commenced to lower LDL cholesterol. Other medications, such as ezetimibe, may also be added with this goal in mind. Aldosterone antagonists (spironolactone or eplerenone) may be used if there is evidence of left ventricular dysfunction after an MI, ideally after beginning treatment with an ACE inhibitor.

Sources: en.wikipedia.org

Supporting material

== Awards and honors == Sur has received numerous honors, including election as a fellow of the Royal Society, the American Academy of Arts and Sciences, the National Academy of Medicine, the American Association for the Advancement of Science, and the American Institute for Medical and Biological Engineering.

== Function == Msr is ubiquitous and highly conserved. Human and animal studies have shown the highest levels of expression in kidney and liver. It carries out the enzymatic reduction of methionine sulfoxide (MetO), the oxidized form of the amino acid methionine (Met), back to methionine, using thioredoxin to catalyze the enzymatic reduction and repair of oxidized methionine residues. Its proposed function is thus the repair of oxidative damage to proteins to restore biological activity. Oxidation of methionine residues in tissue proteins can cause them to misfold or otherwise render them dysfunctional.

== Research == Roy's researches during his stint in the US was on protein folding and nuclear magnetic resonance studies of DNA and those researches identified the first hydropathy model which helped in predicting the exteriors and interiors of proteins by analyzing sequence information. He is also reported to have performed the complete assignment of a nucleic acid imino proton spectra using Nuclear Overhauser effect, regio-specific isotope labeling of sugars in nucleic acids and working along with Ad Bax and R. H. Griffey, developed an indirect 2D-NMR detection method, all reported to be for the first time. Later focusing his attention on bacteriophage lambda, he studied the gene expression of the bacterial virus using its operator-repressor system. Through his collaborative work with Sankar Adhya in 1998, he elucidated the role of differential contact in the transcription regulation mechanism and demonstrated the theory in many genetic regulatory circuits. His current work is focused on peptide therapeutics and he holds patents for some of his work. Roy has published his research work through a number of articles published in peer-reviewed journals and ResearchGate, an online repository of scientific papers, has listed 155 of them. He is the Co-author of "Chemical Biology of the Genome" published by Elsevier/AP. He is a joint editor of Subcellular Biochemistry, volume on Proteins: Structure, Function, and Engineering published by Plenum Press, New York, USA and Protein-Protein interaction Regulators published by Royal Society of Chemistry, UK.

The World Bektashi Congress, also called the National Congress of the Bektashi, a conference during which members of the Bektashi Community make important decisions, has been held in Albania several times. Since 1945, it has been held exclusively in Tirana. The longest gap between two congresses lasted from 1950 to 1993, when congresses could not be held during Communist rule in Albania. A list of congresses is given below.

In 1848 the new Hanoverian law also provided for presbyteries in these Calvinist parishes, which exactly fit the presbyterian structure of Calvinism. Catholics formed an overall minority in Hanover, but regionally majorities in the former prince-bishoprics. By the annexations in 1803 and 1814, Hanover had become a state of three Christian denominations. In 1824, Hanover and the Holy See thus agreed to integrate diaspora parishes which were located in predominantly Protestant areas, until then supervised by the Roman Catholic Vicariate Apostolic of the Nordic Missions, into the existing dioceses of the former prince-bishoprics, whose diocesan territories were thus extended into the diaspora areas. Jews lived all over Hanover in diaspora. Until 1806, they were not allowed to reside in some areas. By the Westphalian and French annexations in 1807 and 1810, all-male inhabitants in later restituted Hanover became Westphalian or French citizens of equal rights. On 17 March 1808, Napoléon Bonaparte restricted the rights of Jews in the French-annexed territory by his so-called décret infâme. The Jewish congregations became subject to French regional Jewish consistories or the Royal Westphalian Consistory of the Israelites, respectively. In 1813, when Hanover resumed independence and sovereignty, its government deprived the Jews of their legal equality.

Sources: en.wikipedia.org

Frequently asked questions

Which receptor does the compound target?

It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.

How does the albumin-binding group alter behavior?

It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.

What do studies generally measure?

Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.

How does the reactive group attach to albumin?

A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.

Network